Core Viewpoint - DaVita Inc. reported a decline in adjusted earnings per share (EPS) for Q3 2024, missing consensus estimates, despite an increase in revenues driven by higher reimbursement rates and other fluctuations [1][2][9][10]. Financial Performance - Adjusted EPS for Q3 2024 was 2.59,down9.12.50, reflecting a decline of 4.6% year over year [1] - Revenues reached 3.26billion,anincreaseof4.61.11 billion, with a gross margin of 34.1%, expanding by 30 basis points [6] Revenue Breakdown - Dialysis patient service revenues were 3.14billion,up6.3125 million, down 26.2% from the previous year [3] Operational Metrics - Total U.S. dialysis treatments for Q3 were 7,350,784, averaging 93,048 per day, which is a sequential decrease of 0.1% [4] - DaVita served approximately 265,400 patients at 3,113 outpatient dialysis centers as of September 30, 2024 [4] Strategic Developments - During Q3 2024, DaVita opened three and closed 15 dialysis centers in the U.S., while also acquiring one and opening four centers outside the U.S. [5] - The company had around 69,500 patients in risk-based integrated care arrangements, representing 5.4billioninannualizedmedicalspend[5]MarginandCostAnalysis−Adjustedoperatingprofittotaled718.2 million, reflecting a 6.1% increase from the prior year [6] - General & administrative expenses increased by 4.4% year over year to 393.5million[6]FinancialPosition−DaVitaendedQ32024withcashandcashequivalentsof1.09 billion, up from 437.2millionattheendofQ2[7]−TotaldebtattheendofQ3was9.56 billion, compared to 8.99billionattheendofQ2[7]−Cumulativenetcashprovidedbyoperatingactivitieswas1.47 billion, down from 1.57billionayearago[7]FutureOutlook−DaVitareiterateditsadjustedEPSguidancefor2024,projectingarangeof9.25-10.05,withtheZacksConsensusEstimateat9.99 [8]